CRISPR-Cas9 homology-independent targeted integration of exons 1-19 restores full-length dystrophin in mice.

Journal Information

Full Title: Mol Ther Methods Clin Dev

Abbreviation: Mol Ther Methods Clin Dev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, Research & Experimental

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of interests A.A.S. and K.M.F. are inventors on a pending patent application filed by Nationwide Children’s Hospital for the gene editing system presented in this work."

Evidence found in paper:

"We wish to thank Dr. Robert B. Weiss of the University of Utah for his assistance in identifying candidate gRNAs. This study was supported by a Center of Research Translation Grant from the 10.13039/100000069National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR070604). The Ohio State University Comprehensive Cancer Center Genomics Shared Resource is supported by an 10.13039/100000002NIH Center Core Grant (P30CA016058). Figures 2A, 3A, and 4A were created with BioRender.com."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025